Renovaro Biosciences Stock Today
| RENB Stock | 0.61 0.09 17.31% |
Performance3 of 100
| Odds Of DistressLess than 20
|
Renovaro Biosciences is trading at 0.61 as of the 28th of November 2024, a 17.31 percent increase since the beginning of the trading day. The stock's open price was 0.52. Renovaro Biosciences has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Renovaro Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of February 2015 | Category Healthcare | Classification Health Care |
Renovaro Biosciences is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 158.72 M outstanding shares of which 3.41 M shares are at this time shorted by private and institutional investors with about 4.72 trading days to cover. More on Renovaro Biosciences
Moving against Renovaro Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Renovaro Stock Highlights
| CEO Director | David Weinstein | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRenovaro Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Renovaro Biosciences' financial leverage. It provides some insight into what part of Renovaro Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Renovaro Biosciences (RENB) is traded on NASDAQ Exchange in USA. It is located in 2080 Century Park East, Los Angeles, CA, United States, 90067 and employs 25 people. Renovaro Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 96.86 M. Renovaro Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 158.72 M outstanding shares of which 3.41 M shares are at this time shorted by private and institutional investors with about 4.72 trading days to cover.
Renovaro Biosciences generates negative cash flow from operations
Check Renovaro Biosciences Probability Of Bankruptcy
Ownership AllocationRenovaro Biosciences owns a total of 158.72 Million outstanding shares. Renovaro Biosciences has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Renovaro Ownership Details
Renovaro Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citigroup Inc | 2024-09-30 | 61 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 59.1 K | |
| Rhumbline Advisers | 2024-06-30 | 45.2 K | |
| Alliancebernstein L.p. | 2024-06-30 | 37.9 K | |
| Jane Street Group Llc | 2024-06-30 | 35.8 K | |
| Bank Of America Corp | 2024-06-30 | 26.3 K | |
| Corebridge Financial Inc | 2024-06-30 | 26.2 K | |
| Msa Advisors Llc | 2024-09-30 | 25 K | |
| Amvescap Plc. | 2024-06-30 | 23 K | |
| Vanguard Group Inc | 2024-09-30 | 5.7 M | |
| Blackrock Inc | 2024-06-30 | 3.7 M |
Renovaro Biosciences Historical Income Statement
Renovaro Stock Against Markets
Renovaro Biosciences Corporate Executives
Elected by the shareholders, the Renovaro Biosciences' board of directors comprises two types of representatives: Renovaro Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Renovaro. The board's role is to monitor Renovaro Biosciences' management team and ensure that shareholders' interests are well served. Renovaro Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Renovaro Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Serhat Gmrkc | CoFounder Inventor | Profile | |
| Luisa Puche | CFO Secretary | Profile | |
| Francois MSc | COO Development | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Return On Assets (0.15) | Return On Equity (0.90) |
The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.